Time-to-progression in breast cancer: a stratification model for clinical trials.

[1]  S. Tibby,et al.  Early application of generic mortality risk scores in presumed meningococcal disease* , 2005, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[2]  N. Ribelles,et al.  The quotient of number of nodes and tumour size (N/T) from primary breast cancer predicts the clinical course after diagnosis of distant relapse. , 2004, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[3]  G. Bastert,et al.  Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis , 2000, Breast Cancer Research and Treatment.

[4]  K. Eguchi,et al.  A prognostic-factor risk index in advanced non-small-cell lung cancer treated with cisplatin-containing combination chemotherapy , 2004, Cancer Chemotherapy and Pharmacology.

[5]  Christopher J Weir,et al.  Comparison of stratification and adaptive methods for treatment allocation in an acute stroke clinical trial. , 2004, Statistics in medicine.

[6]  S. Pinder,et al.  Prognostic factors for patients with hepatic metastases from breast cancer , 2003, British Journal of Cancer.

[7]  J. Bergh,et al.  Prognostic value of quality of life scores for time to progression (TTP) and overall survival time (OS) in advanced breast cancer. , 2003, European journal of cancer.

[8]  C. Boni,et al.  Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Robertson,et al.  Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  A. Harris,et al.  Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? , 1999, Journal of the National Cancer Institute.

[11]  K. Pettigrew,et al.  Progression in acute stroke: value of the initial NIH stroke scale score on patient stratification in future trials. , 1999, Stroke.

[12]  M. Narabayashi,et al.  Construction and validation of a practical prognostic index for patients with metastatic breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Daniel,et al.  There are no bad anticancer agents, only bad clinical trial designs--twenty-first Richard and Hinda Rosenthal Foundation Award Lecture. , 1998 .

[14]  P. Bruzzi,et al.  Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M. Dhodapkar,et al.  Prognostic factors in elderly women with metastatic breast cancer treated with tamoxifen: An analysis of patients entered on four prospective clinical trials , 1996, Cancer.

[16]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[17]  O. Kallioniemi,et al.  Prognostic factors in recurrent breast cancer: relationships to site of recurrence, disease-free interval, female sex steroid receptors, ploidy and histological malignancy grading. , 1990, British Journal of Cancer.

[18]  C. Kamby.  The pattern of metastases in human breast cancer: methodological aspects and influence of prognostic factors. , 1990, Cancer treatment reviews.

[19]  R Simon,et al.  Sample size considerations for studies comparing survival curves using historical controls. , 1988, Journal of clinical epidemiology.

[20]  G M Clark,et al.  Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  P. Meier.  Stratification in the design of a clinical trial. , 1981, Controlled clinical trials.

[22]  Brunner Kw,et al.  Prognostic factors in metastatic breast cancer. , 1981 .

[23]  M. Fey,et al.  Prognostic factors in metastatic breast cancer. , 1981, Cancer clinical trials.

[24]  D. Fournier,et al.  Growth rate of 147 mammary carcinomas , 1980, Cancer.

[25]  B. W. Brown.  Designing for cancer clinical trials: selection of prognostic factors. , 1980, Cancer treatment reports.

[26]  M Tubiana,et al.  Relation between the pathological nature and the growth rate of human tumors. , 1971, European journal of cancer.

[27]  D.,et al.  Regression Models and Life-Tables , 2022 .